Evidence map›Paper›PMID 40880982›Full record

ArticleImmunomedicine2024

Longitudinal Monitoring of T cell Dynamics in Metastatic Breast Cancer via a Remote Diagnostic Implant.

Ian A Schrack, Rebecca S Pereles, Brian C Ross, Jeffrey A Ma, Russell R Urie, Emily R Irish, Guillermo Escalona, Kate V Griffin, Kathryn Kang, Jacqueline S Jeruss and 1 more

Abstract read
In one paragraph

Article in Immunomedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ian A SchrackDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Rebecca S PerelesDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Brian C RossDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Jeffrey A MaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Russell R UrieDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Emily R IrishDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Guillermo EscalonaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Kate V GriffinDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Kathryn KangDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Jacqueline S JerussDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.
Lonnie D SheaDepartment of Biomedical Engineering, University of Michigan, Ann Arbor; MI, 48109, USA.

Funding

Identifying intercellular circuits driving cell phenotypes within a nicheR01CA243916 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JERUSS, JACQUELINE SARA, SHEA, LONNIE D · 2019 to 2023
$2.3M
Tissue engineering tools for monitoring the cellular and molecular response to therapyR01CA272940 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACQUELINE SARA JERUSS, Lonnie D Shea · 2023 to 2026
$1.7M
Nanoparticles to reprogram innate immune cells and disrupt the metastatic nicheR01EB036030 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JACQUELINE SARA JERUSS, Lonnie D Shea · 2024 to 2026
$1.5M
NCI NIH HHS R01 CA243916NCI NIH HHS R01 CA272940NIBIB NIH HHS R01 EB036030
6 · The paper itself

Abstract

Metastatic triple negative breast cancer poses a significant health challenge due to rapid progression and limited treatment options. Immunotherapies targeting T cell responses against metastatic tumors depend on the presence of specific T cell phenotypes, which dynamically evolve with disease progression and treatment. Herein, we investigate T cell phenotype dynamics throughout metastatic disease progression, focusing on both the metastatic site in the lung and a biomaterial implant that serves as a synthetic metastatic niche, with the latter providing an accessible, non-vital tissue for longitudinal analysis. Regulatory T cells were reduced at the lung and scaffold implant sites of metastasis following disease onset and progression relative to healthy mice, while Th1 and Th17 populations remained relatively stable. CD8+ T cells transitioned from naïve and central memory to effector memory with disease progression. Additionally, functional analyses involving the metastatic tissues suggested the primary T cell suppressive mechanisms was reduced migration, with no impact on T cell activation. Blood-based analyses demonstrated some of these phenotypic dynamics yet does not recapitulate the functional assays. Collectively, the scaffold provides a platform for dynamically monitoring T cell phenotypes and functions similar to the metastatic lung, enabling longitudinal monitoring of disease progression that could stratify patient populations.

Indexed as

biomarkersbiomaterialsimmune monitoringmetastasis

Identifiers

PMID40880982
PMCPMC12382481

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.